INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

THE NEED FOR REBLOZYL

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) defines lack of response to ESAs as7:

<1.5 g/dL rise in hemoglobin by 6-8 weeks of treatment

OR

No decrease in RBC transfusion requirement by 6-8 weeks of treatment

NCCN=National Comprehensive Cancer Network (NCCN®).

Though ESA therapy is recommended for the management of symptomatic anemia in patients with lower-risk MDS…2,8-10

ESAs are more likely to be effective for anemia in patients with:

  • Low RBC transfusion requirements (<2 units)
  • A low serum EPO level (<200 U/L)

Many patients demonstrate no initial response or lose their response to ESAs

EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; MDS=myelodysplastic syndromes; RBC=red blood cell.

Reblozyl® (luspatercept-aamt) package, vial, and syringe

When ESAs fail, REBLOZYL can provide meaningful benefit for your patients

THE NEED FOR REBLOZYL

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) defines lack of response to ESAs as7:

<1.5 g/dL rise in hemoglobin by 6-8 weeks of treatment

OR

No decrease in RBC transfusion requirement by 6-8 weeks of treatment

NCCN=National Comprehensive Cancer Network (NCCN®).

Though ESA therapy is recommended for the management of symptomatic anemia in patients with lower-risk MDS…2,8-10

ESAs are more likely to be effective for anemia in patients with:

  • Low RBC transfusion requirements (<2 units)
  • A low serum EPO level (<200 U/L)

Many patients demonstrate no initial response or lose their response to ESAs

EPO=erythropoietin; ESA=erythropoiesis-stimulating agent; MDS=myelodysplastic syndromes; RBC=red blood cell.

Reblozyl® (luspatercept-aamt) package, vial, and syringe

When ESAs fail, REBLOZYL can provide meaningful benefit for your patients

References: 1. Park S, Hamel J-F, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35(14):1591-1597. 2. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018;32(12):2648-2658. 3. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393-2400. 4. Giraldo P, Nomdedeu B, Loscertales J, et al; ARM study group. Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006;107(12):2807-2816. 5. Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27(6):1283-1290. 6. Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol. 2013;92(5):621-631. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 11, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 8. Di Veroli A, Bellis ED, Rossi V, et al. Clinical use of ESAs in low-risk myelodysplastic syndromes. J Rare Dis Res Treat. 2017;2(6):41-44. 9. Park S, Kelaidi C, Meunier M, et al. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Ann. Hematol. 2020;99(1):7-19. 10. Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2016(1):462-469.